Financials data is unavailable for this security.
View more
Year on year Zhejiang Hisun Pharmaceutical Co Ltd 's revenues fell -13.82% from 12.04bn to 10.37bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 489.05m to a loss of 93.17m.
| Gross margin | 38.03% |
|---|---|
| Net profit margin | -0.98% |
| Operating margin | 0.29% |
| Return on assets | -0.53% |
|---|---|
| Return on equity | -0.92% |
| Return on investment | -0.90% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Hisun Pharmaceutical Co Ltd increased its cash reserves by 14.12%, or 164.47m. The company earned 1.50bn from its operations for a Cash Flow Margin of 14.49%. In addition the company used 338.71m on investing activities and also paid 1.00bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.72 |
|---|---|
| Tangible book value per share | 5.72 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.8712 |
|---|---|
| Quick ratio | 0.6209 |
| Total debt/total equity | 0.6782 |
|---|---|
| Total debt/total capital | 0.397 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -118.69%, respectively.
| Div yield(5 year avg) | 0.67% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -115.78 |
More ▼
